Metachronous Pulmonary Metastases in Soft Tissue Sarcoma: Prognostic Factors and Survival Outcomes Following Metastasectomy
- 12 September 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (6) , 1-8
Abstract
Pulmonary metastasectomy (PM) remains a key component in the management of soft tissue sarcoma (STS) patients with isolated lung metastases. However, data on long-term outcomes and prognostic factors in Indian cohorts remain limited. We retrospectively analyzed 21 patients with previously treated soft tissue sarcoma (STS) who developed metachronous pulmonary metastases and underwent pulmonary metastasectomy (PM) at a tertiary care centre between January 2014 and March 2025. Demographic, clinical, radiological, and pathological variables were assessed. Survival outcomes were analysed using Kaplan–Meier estimates, and prognostic factors were evaluated using both univariate and multivariate Cox regression analyses. The median overall survival (OS) following PM was 66 months (95% CI: 32–85 months), with an estimated 5-year OS of 38% (95% CI: 20%–56%). On univariate analysis, a significantly better disease-free interval post-PM was observed in patients undergoing a single video-assisted thoracoscopic surgery (VATS) (p = 0.006), with ≤ 5 pulmonary nodules (p = 0.037), and with nodules ≤ 2 cm in size (p = 0.009). Other variables, including age, primary tumour site, laterality of nodules, and chemotherapy, showed no significant association with survival. Multivariate analysis did not identify any independent predictors, likely due to the small sample size. Six patients (28.5%) underwent repeat metastasectomy for recurrence. A disease-free interval (DFI) ≥ 12 months was associated with improved OS, although the difference was not statistically significant (p = 0.166). PM offers favourable long-term survival in carefully selected STS patients with metachronous lung metastases. Prognostic indicators such as limited metastatic burden and smaller nodule size are associated with improved outcomes. Further multicentre prospective studies are warranted to validate these findings and refine patient selection criteria.Keywords
This publication has 17 references indexed in Scilit:
- Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcomaClinical & Experimental Metastasis, 2020
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010
- Metastasis in Soft Tissue Sarcomas: Prognostic Criteria and Treatment PerspectivesCancer and Metastasis Reviews, 2002
- EVOLUTION OF THE SURGICAL MANAGEMENT OF PULMONARY METASTASESChest Surgery Clinics of North America, 1998
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patientsCancer, 1996
- Development and Treatment of Pulmonary Metastases in Adult Patients with Extremity Soft Tissue SarcomaAnnals of Surgery, 1993
- The Role of Multimodality Therapy in Soft-tissue SarcomaAnnals of Surgery, 1991
- Management of extremity soft-tissue sarcomaThe American Journal of Surgery, 1989
- Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomasThe Journal of Thoracic and Cardiovascular Surgery, 1984